Approved as monotherapy for adults with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm), HER2-negative locally advanced or metastatic breast cancer — and, in combination with enzalutamide, for adults with metastatic castration-resistant prostate cancer (mCRPC), regardless of homologous recombination repair (HRR) gene mutation status.